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Abstract
Background: Total plasma homocysteine (tHcy) concentra-
tion is increased in elderly patients with mental illness. Also,
patients with vascular disease have significantly higher plas-
ma tHcy concentration compared with patients without vas-
cular disease. Apolipoprotein E (apoE) status is associated
with cardiovascular disease and a major genetic risk factor
is inheritance of the e4 allele. In the present study, we inves-
tigated the association between plasma tHcy and apoE status.
Methods: The relation between apoE status, plasma tHcy
and vascular disease was investigated in a cohort of consec-
utively enrolled elderly patients with mental illness (ns328).
Results: Plasma tHcy concentrations were increased
(p-0.01) in carriers of APOE4 (13.6 mmol/L; 9.2–21.7
mmol/L) compared to non-carriers (12.4 mmol/L; 8.3–19.9
mmol/L). The proportion of patients with vascular disease
was significantly (p-0.001) increased among carriers (61%)
compared to non-carriers (42%). An increased percentage
(p-0.001) of APOE4 carriers was observed in patients with
Alzheimer’s disease (AD) with (71%) or without vascular
disease (42%), and in patients with vascular dementia (VaD)
(54%) compared to a reference group (34%).
Conclusions: Since carriers of APOE4 showed an increased
likelihood of vascular disease, these patients need more
intensive control of other modifiable vascular risk factors.
Furthermore, the association between plasma tHcy and the
presence of APOE4 might be attributed to an increased pro-
portion of vascular disease in APOE4 carriers.
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Introduction
Apolipoprotein E (apoE) plays a central role in lipid metab-
olism as a component of very low-density lipoproteins and
chylomicrons (1). The APOE gene, located at chromosome
19, is polymorphic with three common alleles – e2, e3 and
e4 (2). One genetic risk factor associated with late-onset Alz-
heimer’s disease (AD) is inheritance of the e4 allele (2, 3).
This allele is also associated with cardiovascular disease,
unlike the other two common alleles e2 and e3 (2–4).
Many studies have reported significantly higher total
plasma homocysteine (tHcy) in elderly patients with mental
illness compared with control subjects (5–8). The concentra-
tion of plasma tHcy is influenced by several factors and their
interaction (9, 10). Some of these factors are age, cobalamin/
folate status, renal function and the presence of vascular dis-
ease. Many clinical and epidemiological studies published
during the last 20 years show that even mild hyper-
homocysteinemia is associated with vascular disease (9,
11–16). Therefore, we studied elderly patients with mental
illness with respect to the presence of vascular disease (5,
17–20). Briefly, our findings showed that patients with men-
tal illness and vascular disease had significantly higher plas-
ma tHcy concentrations compared with patients with mental
illness but without vascular disease (5, 17–20), and that
increased plasma tHcy was associated primarily with the
presence of vascular disease and not related to a specific
psychogeriatric diagnosis.
Vascular disease plays an important role in cognitive
impairment in elderly patients with mental illness (21). There
is a complex relation between vascular disease and dementia
(22). Vascular dementia (VaD) and AD together account for
the vast majority of cases of dementia. AD, the most com-
mon type of degenerative dementia, has long been consid-
ered to be a primarily degenerative brain disease. However,
many patients with AD also have vascular disease contrib-
uting to brain pathology (23). An increasing number of epi-
demiological studies have provided further support for the
suggestion that the presence of vascular disease or traditional
vascular risk factors is associated with AD (24–27). VaD is
considered to be the second most common cause of dementia
and may result from several different types and locations of
cerebrovascular lesions. The coexistence of VaD and AD
may be the most common cause of dementia, i.e., mixed
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Table 1 Diagnoses of patients with and without vascular disease according to APOE status.
Number of APOE2/2 APOE2/3 APOE2/4 APOE3/3 APOE3/4 APOE4/4
patients
Number of genotypes 328 3 37 12 150 95 31
Dementia of Alzheimer type 61 5 22 22 12
Mixed vascular and Alzheimer 17 2 2 4 7 2
type dementia
Frontal lobe degeneration of 11 2 1 4 2 2
non-Alzheimer type
Vascular dementia 39 3 4 15 15 2
Unspecified dementia 5 4 1
Other specified types of 13 1 5 6 1
dementia
Delirium 2 2
Depression 23 1 2 1 13 6
Other non-organic psychiatric 13 1 9 1 2
disorders
Mild cognitive impairment 85 1 11 3 44 21 5
Subjective cognitive impairment 59 1 10 1 28 15 4
No vascular disease 166 1 20 3 91 40 11
Vascular disease 162 2 17 9 59 55 20
dementia where both degenerative and vascular injuries are
present (23, 28).
The public health burden of AD and VaD threatens to soar
in the next few decades. There is a growing need to modify
known risk factors for cognitive dysfunction, and one mod-
ifiable risk factor is vascular disease (21, 22). Proper control
of vascular disorders may prevent or delay the onset of cog-
nitive impairment (21, 22, 29). We have previously investi-
gated different markers for vascular disease and their relation
to the presence of vascular disease and plasma tHcy concen-
trations in consecutively enrolled elderly patients with men-
tal illness (29–31). In the present study, we further extend
those studies by investigating the relation between apoE stat-
us, a genetic risk marker of vascular disease, the presence of
vascular disease and plasma tHcy concentrations in elderly
patients with mental illness. By investigating markers for
vascular disease in these patients, it might be possible to
identify patients in need of more intensive control of their




The present study population consisted of 328 patients consecutive-
ly enrolled (151 males and 177 females, 69 (51–83) years, median
and 10th–90th percentiles) who were referred to the Psychogeriatric
Department at Lund University Hospital for diagnostic assessments
and treatment. Patients on any type of ongoing vitamin therapy were
excluded from the study. The diagnosis was based on psychiatric,
neurological, somatic, laboratory investigations, psychometric test-
ing, measurements of regional cerebral blood flow, electroenceph-
alography, and computer tomography scan (CT) or magnetic
resonance imaging (5). The majority of cases were living in their
own homes, alone or with relatives. The diagnosis of the psycho-
geriatric diseases was based on the DSM-IV criteria (32). Further-
more, patients with VaD fulfilled the NINDS-AIREN criteria (33)
for VaD. Patients with AD were diagnosed in accordance with the
NINCDS-ADRDA criteria (34). Organic dementia was diagnosed in
146 patients, 61 patients were diagnosed with AD, 11 patients with
frontal lobe degeneration of non-Alzheimer type (FTD), 39 patients
with VaD, 17 patients with mixed vascular and Alzheimer type
dementia (MX), 13 patients with other types of dementia (Oth Dem)
and five patients with dementia NUD. One hundred and eighty-two
patients suffered from non-organic mental diseases, two patients had
delirium (Del), 23 patients depression (Depr), 13 patients other psy-
chiatric disorders (Oth Psych, mainly psychosis), and 85 patients
had mild cognitive impairment (MCI) (35). In addition, 59 patients
presented with subjective symptoms of cognitive impairment but
normal psychometric tests. They had normal CT and otherwise were
apparently healthy. These patients were treated as a separate group
of patients called subjective cognitive impairment (SCI). The APOE
genotypes in the different diagnostic groups are shown in Table 1.
The study was approved by the Ethical Committee of the University
of Lund. Informed consent to participate was given by all subjects
(or relatives if the patients were unable to communicate).
The patients were divided into two groups according to the pres-
ence or absence of vascular disease. Both cerebral and extra-cerebral
vascular diseases were included in the group of patients with vas-
cular disease. The presence of vascular disease in the patients was
based on diagnosis and/or symptoms indicating vascular disease as
indicated in their medical records. One group (ns162) consisted of
patients with vascular disease and included diagnoses/symptoms,
such as VaD, cerebral infarction, transitory ischaemic attacks, myo-
cardial infarction, angina pectoris, peripheral vascular disease, atrial
fibrillation, and hypertension. In another group of 166 patients, there
was no indication of any vascular disease.
Assays
Blood samples for homocysteine determination were collected in
evacuated tubes containing EDTA at about 8 a.m. following an
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Table 3 Plasma tHcy, serum cobalamin (S-Cob), serum folate (S-
Fol), serum creatinine (S-Creat), patients with and without vascular




P-tHcy, mmol/L 12.4 (8.3–9.9) 13.6 (9.2–21.7)b
S-Cob, pmol/L 307 (183–468) 291 (177–486)
S-Fol, nmol/L 13.0 (7.5–25.3) 14.0 (8.2–22)
S-Creat, mmol/L 75 (58–108) 78 (57–114)
Vascular disease, n 78 (41%) 84 (61%)a
No vascular disease, n 112 (59%) 54 (39%)a
Dementia, n 67 (35%) 79 (57%)b
Non-dementia, n 123 (65%) 59 (43%)b
ap-0.001; bp-0.01. Non-carriers are compared to carriers. Median,
10th–90th percentiles are presented for plasma tHcy, S-Cob, S-Fol
and S-Creat, whereas number and percentage are presented for the
patients.
Table 2 Plasma tHcy concentration and age according to APOE status.
APOE2/2 APOE2/3 APOE2/4 APOE3/3 APOE3/4 APOE4/4
Number of genotypes 3 37 12 150 95 31
P-tHcy, mmol/L 13.5 (5.8–16.2) 12.8 (8.8–20.1) 12.9 (8.5–24.1) 12.4 (8.3–20) 13.9 (9.3–22.5) 13.1 (9.1–20)
Age, years 73 (60–86) 68 (49–84) 72 (55–83) 64 (49–84) 72 (53–83) 71 (53–81)
Median, 10th–90th percentiles are presented.
overnight fast and centrifuged within 15 min at 3000=g for 5 min.
Plasma tHcy was measured with HPLC after reduction of disulphide
bonds with dithiothreitol and deproteinisation with sulphosalicylic
acid (36). The upper reference limit (95th percentile) for plasma
tHcy in a healthy elderly population without folate fortification is
19.9 mmol/L (17, 18).
APOE genotyping was performed using a method of restriction
genotyping as described by Hixson (37). The percentage of APOE4
carriers (APOE2/E4, E3/E4 and E4/E4) in a healthy Swedish pop-
ulation is about 30% (38).
Serum cobalamin (S-Cob) and serum folate (S-Fol) concentra-
tions were determined using competitive protein binding assays
(Roche Diagnostics, Mannheim, Germany; Modular Analytics
E170). For S-Cob we used the reference interval of 150–650
pmol/L (5). The reference interval according to the manufacturer
(Roche Diagnostics) for S-Fol in individuals without folate fortifi-
cation is 7–39 nmol/L.
Serum creatinine (S-Creat) concentrations (upper reference limit
105 mmol/L for males and 95 mmol/L for females) were measured
with an enzymatic method (Roche Diagnostics; Modular Analytics
P).
Serum C-reactive protein (CRP) (upper reference limit 3.0 mg/L)
was measured in a subpopulation of the present study population
(ns58) with a routine method (Roche Diagnostics; Modular Ana-
lytics P).
Statistics
The results are presented as medians and 10th–90th percentiles. The
following two-tailed tests at the 5% level of significance were used
to evaluate the study: Kruskal-Wallis one-way analysis of variance
with Bonferoni-correction in cases with three or more independent
samples, Mann-Whitney U-test for two independent samples. The
x2-test was used for comparison of frequencies between APOE4
carriers and non-carriers (Table 3) and percentage of APOE4 carriers
in different diagnostic groups (Table 4). A general linear model
(GLM) was used to identify factors with effects on plasma tHcy
concentrations. Logistic regression analysis was performed in which
the presence or absence of vascular disease was included as the
dependent variable.
Results
The most frequent APOE genotype was e3/e3 (ns150), and
e3/e4 (ns95), followed in descending order by e3/e2
(ns37), e4/e4 (ns31), e4/e2 (ns12), and e2/e2 (ns3).
Diagnoses and patients with and without vascular disease in
the different apoE status are shown in Table 1. Plasma tHcy
concentrations were increased (p-0.001) in patients with
vascular disease (14.1; 9.1–21.2 mmol/L, ns162) compared
with patients without vascular disease (11.6; 8.5–19.3,
ns166). Plasma tHcy concentrations and age according to
APOE status are shown in Table 2. There were no significant
differences in these variables between the different APOE
genotypes.
Table 3 shows a comparison of APOE4 carriers to non-
carriers. Plasma tHcy concentrations were increased in car-
riers compared to non-carriers. Age correction of plasma
tHcy did not change the significant difference. There was no
significant difference between carriers and non-carriers with
respect to use of drugs that may affect plasma tHcy concen-
trations such as folate, cobalamin or vitamin B6 antagonists.
No association with APOE4 status was observed with respect
to S-Creat, S-Cob or S-Fol. The proportion of patients with
vascular disease was significantly increased among carriers
compared to non-carriers, whereas patients without vascular
disease exhibited a significantly increased proportion among
non-carriers compared to carriers. Likewise, patients with
dementia exhibited a significantly higher proportion among
carriers compared to non-carriers, and patients without
dementia exhibited a significantly increased proportion
among non-carriers compared to carriers.
In Table 4, the percentage of APOE4 carriers is presented
in some diagnostic groups and compared to patients with
SCI, since these patients exhibited a normal percentage of
APOE4 carriers. Patients with AD, with or without vascular
disease, showed a significantly increased percentage of
APOE4 carriers compared to patients with SCI. Patients with
AD and vascular disease also showed an increased percent-
age of APOE4 carriers (p)0.001) compared to AD patients
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Table 4 Age, plasma tHcy, and percentage of APOE4 carriers in different diagnostic groups.
Number Age, years P-tHcy, mmol/L APOE4
carriers, %
AD 61 72 (54–87)a 15.0 (10.3–21.6)a 56a
AD with vascular disease 28 72 (61–84)a 15.1 (10.7–20.5)b 71a
AD without vascular disease 33 71 (52–90)a 14.5 (10–22.8)c 42a
MCI 85 62 (50–77)c 11.7 (8.8–17.3)c 34
MCI with vascular disease 40 69 (54–78)a 12.5 (9–21.5)c 37
MCI without vascular disease 45 57 (47–72) 11.3 (8.4–16.1) 31
VaD 39 80 (69–87)a 17.0 (9.5–25.7)a 54a
Depr 29 66 (48–84)c 11.4 (7.4–16.7) 30
SCI 59 57 (41–73) 10.7 (7.8–15.7) 34
ap-0.001; bp-0.01; cp-0.05. The different diagnostic groups are compared with patients with SCI. Kruskal-Wallis and Mann-Whitney
tests were used to detect significant changes in plasma tHcy levels and age. Median, 10th–90th percentiles are presented for age and plasma
tHcy, whereas percentages are presented for APOE4 carriers.
Table 5 General linear model estimates of factors with potential
impact on plasma tHcy concentrations (dependent variable).





Presence of APOE4 status (yes/no) –0.193 0.847
without vascular disease. Patients with MCI, with or without
vascular disease, exhibited no significant increase in carriers
compared to patients with SCI, whereas patients with VaD
showed an increased percentage of APOE4 carriers com-
pared to patients with SCI.
Plasma tHcy concentrations were increased in AD patients
with or without vascular disease, in MCI patients with vas-
cular disease, and in patients with VaD compared to patients
with SCI (Table 4). All diagnostic groups, except MCI with-
out vascular disease, exhibited older age than patients with
SCI. In addition, there were no significant differences
between S-Cob, S-Fol or S-Creat among the different diag-
nostic groups shown in Table 4 (data not shown).
In a subgroup that included 58 randomly selected patients,
43 had normal serum CRP and 15 had increased serum CRP
(above 3 mg/L). Carriers of APOE4 with both normal and
increased serum CRP showed no significant changes in plas-
ma tHcy concentrations compared to non-carriers (normal
CRP: carriers 12.5, 7.9–23.7 mmol/L, ns20 and non-carri-
ers 10.4, 7.1–22.7, ns23; increased CRP: carriers 13.3,
6.3–16.7 mmol/L, ns8 and non-carriers 9.0, 6.7–16.0,
ns8).
Multivariate analysis (GLM) that included age, S-Fol, S-
Cob, S-Creat, and APOE4 status showed that age, S-Fol, S-
Creat and S-Cob significantly predicted plasma tHcy
concentrations (Table 5). Logistic regression analysis in all
patients, with the presence or absence of vascular disease as
the dependent variable, showed that plasma tHcy, adjusted
for its significant predictors (age, S-Fol, S-Creat and S-Cob),
and the presence of APOE4 status were significant predictors
of vascular disease (adjusted plasma tHcy – t-value 3.413,
p-0.001; presence of APOE4 status – t-value 2.959,
p-0.01).
Discussion
The present study population consisted of consecutively
enrolled patients with mental illness. Approximately half of
the patients had co-existent vascular disease and ;40% had
dementia. The current study showed that in these elderly
patients with mental illness, plasma tHcy concentrations
were increased in APOE4 carriers compared to non-carriers.
In previous investigations (39–41), no association was
observed between plasma tHcy and APOE4 status. Those
investigations, however, did not focus specifically on the
association of interest, and two (39, 40) had small population
sizes. In a recent study (42), APOE4 carriers in an elderly
healthy population had an even lower risk of hyperhomo-
cysteinemia than did non-carriers, but only if the carriers did
not have increased CRP concentrations. The authors (42)
suggested that this finding could possibly be attributed to
CRP and plasma tHcy competing for the same mechanism
(perhaps a lipoprotein carrier) that favours their clearance
from blood in APOE4 carriers. However, in a small sub-
population of the present study population we could observe
no such association between APOE4 carrier status and con-
centrations of plasma tHcy and serum CRP. Carriers of
APOE4 with both normal and increased serum CRP showed
a tendency towards increased plasma tHcy (not significant)
compared to non-carriers. The discrepant findings might pos-
sibly be explained by different selection criteria and different
populations. In the present study, patients with vascular dis-
ease showed an increased proportion among APOE4 carriers,
which is in agreement with previous studies (2–4). The
increased proportion of patients with vascular disease in
APOE4 carriers could explain the increased plasma tHcy
concentrations in carriers, since the presence of vascular dis-
ease is associated with increased concentrations of plasma
tHcy (9, 11–16).
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Clarification of the role of vascular risk factors for cog-
nitive dysfunction is important since these may serve as tar-
gets for strategies for prevention (21, 22). Few studies have
examined the effect of vascular risk factors on dementia pro-
gression after establishing a diagnosis of AD. Mielke et al.
(43) have shown that atrial fibrillation, hypertension and
angina pectoris were associated with a greater rate of decline
and thus may represent modifiable risk factors for secondary
prevention in AD. Likewise, Song et al. (44) observed that
AD with silent cerebral infarction showed a more severe cog-
nitive decline than AD without vascular disease, indicating
that cerebrovascular disease contributes to the severity of
cognitive decline. Also, Sheng et al. (45) showed that AD
with coexisting cerebral infarction (satisfying criteria for
VaD) was associated with faster progression of dementia.
These findings suggest that prevention of cerebrovascular
disease may play an important role in preventing the rapid
cognitive decline of AD.
The percentage of APOE4 carriers in normal subjects has
been reported to be about 30% (38). An increased percentage
of APOE4 carriers was observed in AD patients with or with-
out vascular disease, which is in agreement with previous
studies (2, 3). In addition, AD patients with vascular disease
exhibited a higher percentage (71%) of APOE4 carriers than
AD patients without vascular disease (42%). In previous
investigations, plasma tHcy concentrations were also
observed to be increased in AD patients with vascular dis-
ease compared to AD patients without vascular disease (20,
29). ApoE4 might contribute to AD pathology by interacting
with multiple factors through various pathways (46). For
example, interactions with the amyloid b-peptide and the
amyloid cascade may lead to cognitive decline and neuro-
degeneration. However, since patients with AD and vascular
disease showed a higher percentage of APOE4 carriers than
patients with AD without vascular disease, it is possible that
apoE4 primarily reflects the presence of vascular disease. In
agreement with the findings of Religa et al. (39), patients
with MCI did not show an increased percentage of APOE4
carriers. Most previous studies have also demonstrated an
association between APOE4 carriers and patients with VaD
(47). Although not all studies found a significant association,
some studies (47) that did not find a significant association
did find a tendency towards a greater frequency of APOE4
carriers in VaD. In the present study, we observed a signif-
icant increase in carriers. However, the number of patients
with VaD was relatively small.
APOE4 carriers have been associated with cognitive
decline in elderly subjects (41, 48). In accordance with these
findings, we observed an increased frequency of patients
with dementia in the group of APOE4 carriers compared to
non-carriers. One possible reason for the association of the
APOE4 genotype and cognitive impairment is that the
APOE4 genotype is related to vascular disease which, in
turn, is related to cognitive impairment (21).
In the present study, we have investigated APOE4 status
as a possible risk marker for vascular disease in elderly
patients with mental illness. APOE4 carriers showed an
increased proportion in patients with vascular disease. Like-
wise, the presence of APOE4 status predicted the presence
of vascular disease. The presence of APOE4 status in patients
with mental illness might therefore be useful to identify
patients at risk of rapid progression of vascular disease and
consequently also of cognitive decline. Therefore, carriers of
APOE4 might require more intensive control of other mod-
ifiable vascular risk factors, such as blood pressure or cho-
lesterol. Furthermore, the association between plasma tHcy
and the presence of apoE4 might be attributed to an increased
proportion of vascular disease in APOE4 carriers.
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